



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/806,537	07/05/2001	Y Tom Tang	PF-0612 USN	1263

22428 7590 08/10/2004

FOLEY AND LARDNER  
SUITE 500  
3000 K STREET NW  
WASHINGTON, DC 20007

EXAMINER

LANDSMAN, ROBERT S

ART UNIT PAPER NUMBER

1647

DATE MAILED: 08/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/806,537

**Applicant(s)**

TANG ET AL.

**Examiner**

Robert Landsman

**Art Unit**

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 06 July 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above claim(s) 7,8,16-18 and 20 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-6,9-15 and 19 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 28 March 2001 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 7/6/04.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: Sequence Comparisons A-E

Art Unit: 1647

## **DETAILED ACTION**

### ***1. Formal Matters***

- A. The Election dated 7/6/04 has been entered into the record.
- B. Claims 1-20 were pending and were subject to restriction in the Office Action mailed 5/3/04. Applicants elected Group I, claims 1-6, 9-15 and 19, with traverse. The traversal will be discussed below. Claims 7, 8, 16-18 and 20 have been withdrawn as being drawn to a non-elected invention. Therefore, claims 1-6, 9-15 and 19 are the subject of this Office Action.

### ***2. Answer to Traversal***

- A. Applicants argue that SEQ ID NO:9, which is the polynucleotide encoding the polypeptide of SEQ ID NO:1 should be searched. This argument is persuasive. Therefore, SEQ ID NO:1 and 9 will be searched.

### ***3. Specification***

- A. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The following title is suggested: G protein-coupled receptor proteins, encoding nucleic acids and methods of using the proteins.

### ***4. Claim Objections***

- A. Claims 1-6, 9-15 and 19 are objected to since they recite non-elected SEQ ID NOs.

### ***5. Claim Rejections - 35 USC § 101***

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

- A. Claims 1-6, 9-15 and 19 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by a specific, substantial and credible asserted utility or a well established utility. These claims are directed to a protein of SEQ ID NO:1, its encoding polynucleotide of SEQ ID NO:9 and methods of treating disorders. However, the invention encompassed by these claims has no apparent or disclosed patentable utility. This rejection is consistent with the current utility guidelines, published 1/5/01, 66 FR

Art Unit: 1647

1092. The instant application has provided a description of an isolated protein. However, the instant application does not disclose a specific and substantial biological role of this protein or its significance.

However, it is clear from the instant specification that the claimed receptor is what is termed an "orphan receptor" in the art. The instant application does not disclose the biological role of the claimed protein or its significance in relation to any disease state. Applicants disclose in the specification that the claimed receptor is homologous to human epididymis-specific seven transmembrane receptor HE6. However, homology alone is not sufficient. There is little doubt that, after complete characterization, this protein will probably be found to have a patentable utility. This further characterization, however, is part of the act of invention and, until it has been undertaken, Applicants' claimed invention is incomplete.

The instant situation is directly analogous to that of which was addressed in *Brenner v. Manson*, 148 U.S.P.Q. 689 (Sus. Ct, 1966), in which a novel compound which was structurally analogous to other compounds which were known to possess anticancer activity was alleged to be potentially useful as an antitumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 U.S.C. 101, which required that an invention must have either an immediate obvious or fully disclosed "real-world" utility. The court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility," "[u]nless and until a process is refined and developed to this point - where specific benefit exists in currently available form - there is insufficient justification for permitting an applicant to engross what may prove to be a broad field," and "a patent is not a hunting license," "[i]t is not a reward for the search, but compensation for its successful conclusion."

The specification discloses that the polypeptide of the invention has sequence similarity to a known human epididymis-specific seven transmembrane receptor HE6. Based on the structural similarity, the specification asserts that the newly disclosed SEQ ID NO:1 and 9 have similar activities. The assertion that the disclosed proteins have biological activities similar to known receptors cannot be accepted in the absence of supporting evidence, because, generally, the art acknowledges that function cannot be predicted based solely on structural similarity to a protein found in the sequence databases. For example, Skolnick et al. (2000, Trends in Biotech. 18:34-39) state that knowing the protein structure by itself is insufficient to annotate a number of functional classes, and is also insufficient for annotating the specific details of protein function (see Box 2, p. 36). Similarly, Bork (2000, Genome Research 10:398-400) states that the error rate of functional annotations in the sequence database is considerable, making it

Art Unit: 1647

even more difficult to infer correct function from a structural comparison of a new sequence with a sequence database (see especially p. 399). Such concerns are also echoed by Doerks et al. (1998, Trends in Genetics 14:248-250) who state that (1) functional information is only partially annotated in the database, ignoring multi functionality, resulting in underpredictions of functionality of a new protein and (2) overpredictions of functionality occur because structural similarity often does not necessarily coincide with functional similarity. Smith et al. (1997, Nature Biotechnology 15:1222-1223) remark that there are numerous cases in which proteins having very different functions share structural similarity due to evolution from a common ancestral gene.

Brenner (1999, Trends in Genetics 15:132-133) argues that accurate inference of function from homology must be a difficult problem since, assuming there are only about 1000 major gene superfamilies in nature, then most homologs must have different molecular and cellular functions. Finally, Bork et al. (1996, Trends in Genetics 12:425-427) add that the software robots that assign functions to new proteins often assign a function to a whole new protein based on structural similarity of a small domain of the new protein to a small domain of a known protein. Such questionable interpretations are written into the sequence database and are then considered facts.

Therefore, based on the discussions above concerning the specific examples of structurally similar proteins that have different functions, along with the art's recognition that one cannot rely upon structural similarity alone to determine functionality, the specification fails to teach the skilled artisan the utility of the claimed polypeptide of SEQ ID NO:1 and the polynucleotides of SEQ ID NO:9 which are only known to be homologous to a known receptor. Therefore, the instant claims are drawn to a polynucleotide encoding a protein which has a yet undetermined function or biological significance. There is no actual and specific significance which can be attributed to said protein identified in the specification, or any association with a disease state. For this reason, the instant invention is incomplete. In the absence of a knowledge of the natural ligands or biological significance of this protein, there is no immediately obvious patentable use for it. To employ a protein of the instant invention in the identification of substances which bind to and/or mediate activity of the said receptor is clearly to use it as the object of further research which has been determined by the courts to be a non-patentable utility. Since the instant specification does not disclose a "real-world" use for said protein then the claimed invention is incomplete and, therefore, does not meet the requirements of 35 U.S.C. 101 as being useful.

**Furthermore, since the nucleic acid and protein of the invention are not supported by a specific and substantial asserted utility or a well established utility, the vector, host cell as well as methods for producing and using the claimed polypeptide also lack utility.**

Art Unit: 1647

**6. Claim Rejections - 35 USC § 112, first paragraph - scope of enablement**

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

A. Claims 1-6, 9-15 and 19 are rejected under 35 U.S.C. 112, first paragraph, as failing to adequately teach how to use the instant invention. Specifically, since the claimed invention is not supported by a specific, substantial and credible asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

B. Furthermore, even if claim 1-6, 9-15 and 19 possessed utility under 35 USC 101, they would still be rejected under 35 U.S.C. 112, first paragraph, because the specification, while then being enabling for the protein of SEQ ID NO:1 and the polynucleotide of SEQ ID NO:9, does not reasonably provide enablement for proteins which are at least **"70% or 90%"** identical to SEQ ID NO:1 or 9, **"fragments"** thereof, or which **"hybridize"** to SEQ ID NO:9. Furthermore, the specification is not enabled for **"host cells"** which are not **"isolated,"** for **"pharmaceutical compositions"** or for **"methods of treating disorders"** with these compositions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

In In re Wands, 8USPQ2d, 1400 (CAFC 1988) page 1404, the factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

First, the breadth of the claims is excessive with regard to claiming all proteins and polynucleotides which are "at least 70% or 90% identical" to SEQ ID NO:1 or 9, respectively, or those which "hybridize" under stringent conditions to SEQ ID NO:9. Nucleic acid molecules which are "at least 70% or 90% identical" to SEQ ID NO:9," which "hybridize" to SEQ ID NO:9, or which comprise fragments of SEQ ID NO: 9 would have one or more nucleic acid substitutions, deletions, insertions and/or additions to the polynucleotide of SEQ ID NO:9. Similarly, proteins which are "at least 70% or 90% identical" to the protein of SEQ ID NO:1, or comprise fragments thereof, would encode for a protein

Art Unit: 1647

with one or more amino acid substitutions, deletions, insertions and/or additions to the protein of SEQ ID NO:1.

Applicants provide no guidance or working examples of nucleic acid molecules which hybridize to SEQ ID NO:1, or of proteins which are at least 70% or 90% identical to SEQ ID NO:1, or polynucleotides which are at least 70% or 90% identical to SEQ ID NO:9, nor do they provide a *function* of these nucleic acid molecules, or proteins. Furthermore, fragments can be as few as one amino acid, or nucleic acid. Applicants have provided no guidance as to what critical residues are required to maintain the functional characteristics of any protein other than that of the full-length of SEQ ID NO:1 or the polynucleotide of SEQ ID NO:9. Furthermore, it is not predictable to one of ordinary skill in the art how to make a functional protein which is less than 100% identical to that of SEQ ID NO:1, or the polynucleotide of SEQ ID NO:9.

In addition, Applicants are not enabled for host cells which are not "isolated." As stand, claim 13 reads on gene-therapy since the cells transfected with the DNA could be in, for example, a human host. Claims 15 and 19 recite "pharmaceutical compositions." However, Applicants have not provided any guidance and working examples of the use of the protein of the invention to treat any disorder, nor are Applicants enabled for the scope of claim 19 since there are no examples of any disorders to be treated.

In summary, the breadth of the claims is excessive with regard to Applicants claiming all proteins and polynucleotides which are at least "70% or 90%" identical to SEQ ID NO:1 or 9, "fragments" thereof, or polynucleotides which "hybridize" to SEQ ID NO:9. There is also a lack of guidance and working examples of these nucleic acid molecules and proteins as well as which residues are critical for protein function. Similarly, the specification does not enable host cells which are not isolated, pharmaceutical compositions or methods of treating any claimed disorder. These factors, along with the lack of predictability to one of ordinary skill in the art as to how to make a functional proteins and polynucleotides other than that of SEQ ID NO:1 and 9, or how to use pharmaceutical compositions to treat the claimed disorders, leads the Examiner to hold that undue experimentation is necessary to practice the invention as claimed.

Art Unit: 1647

**7. Claim Rejections - 35 USC § 112, first paragraph – written description**

A. Claims 1-6, 9-15 and 19 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

These are genus claims. Nucleic acid molecules which are “**at least 70% or 90% identical**” to SEQ ID NO:9,” which “**hybridize**” to SEQ ID NO:9, or which comprise “**fragments**” of SEQ ID NO: 9 would have one or more nucleic acid substitutions, deletions, insertions and/or additions to the polynucleotide of SEQ ID NO:9. Similarly, proteins which are “at least 70% or 90% identical” to the protein of SEQ ID NO:1, or comprise fragments thereof, would encode for a protein with one or more amino acid substitutions, deletions, insertions and/or additions to the protein of SEQ ID NO:1.

The specification and claims do not indicate what distinguishing attributes are shared by the members of the genus. Thus the scope of the claims includes numerous structural variants, and the genus is highly variant because a significant number of structural differences between genus members is permitted. The specification and claims do not provide any guidance as to what changes should be made. Structural features that could distinguish compounds in the genus from others in the nucleic acid or protein class are missing from the disclosure. No common structural attributes identify the members of the genus. The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is what is needed. Since the disclosure fails to describe the common attributes or characteristics that identify members of the genus, and because the genus is highly variant, SEQ ID NO:1 and 9, or molecules which hybridize to the polynucleotides of SEQ ID NO:9 (which could be at least thousands of molecules) are insufficient to describe the genus. One of skill in the art would reasonable conclude that the disclosure fails to provide a representative number of species to describe the genus. Thus, Applicant was not in possession of the claimed genus at the time the invention was made.

This rejection also pertains to the claimed “**pharmaceutical compositions**” and “**methods of treating disorders.**” The specification does not provide adequate written description of “pharmaceutical compositions” to treat any disorder, nor does it provide written description of any disorders to be treated with these compositions.



Art Unit: 1647

**8. Claim Rejections - 35 USC § 112, second paragraph**

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

A. Claim 5 is vague and indefinite since the claim recites “stringent conditions.” It is not known what these conditions are. Nucleic acid molecules which hybridize under conditions of “low” stringency would not necessarily hybridize under conditions of “high” stringency. Furthermore, not all conditions of “high” or “low” stringency, for example, are the same. Therefore, it is required that Applicants amend the claims to recite the exact hybridization conditions without using indefinite phrases such as “*for example*” **without adding new matter.**

B. Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: a conclusion step demonstrating when the claimed method has been performed (i.e. when the objective of the claim has been reached). The claim recites a method of treating a disorder. However, there is no steps which determine, or identify, when the claimed disorder has been treated.

**9. Claim Rejections - 35 USC § 102**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

A. Claims 1-6, 9-15 and 19 are rejected under 35 U.S.C. 102(a) as being anticipated by Wood et al. (WO 99/46281). The claims recite a polypeptide of SEQ ID NO:1, fragments thereof, as well as encoding polynucleotides, or fragments thereof. The claims also recite vectors, host cells, methods of making polypeptide, pharmaceutical compositions and methods of treating a disorder. Wood meet these limitations (Abstract; p296-299; Sequence Comparisons A, C, D). They teach a protein and polynucleotide which are 100% identical to SEQ ID NO:1 and 9 of the present invention. The artisan would immediately envision pharmaceutical compositions as well as methods of treating diseases (Examples 108 and 109 of page 306; lines 25-30 of page 132).

Art Unit: 1647

B. Claims 1-6 and 9-11 are rejected under 35 U.S.C. 102(a) as being anticipated by Liu et al. (Genomics 1999). Liu teach a polynucleotide encoding a protein (or fragment thereof) which is 99.9% identical to that of the present invention (Sequence Comparison B). This polynucleotide would be expected to hybridize to SEQ ID NO:9.

C. Claims 1-6, 9-11 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent 6,183,968. The patent discloses a polynucleotide which is 80% identical to that of the present invention (Sequence Comparison E). The artisan would immediately envision that this polynucleotide encodes a fragment of SEQ ID NO:1.

#### **10. Claim Rejections - 35 USC § 103**

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

A. Claims 12-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Liu or US Patent 6,183,968 each in view of Wood et al. The claims of the present invention as well as the teachings of all cited references are seen in the above rejection under 35 USC 102. Neither Liu, nor '968 teach vectors, host cells, or methods of making protein. However, Wood do teach these limitations.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the invention of Wood et al. by substituting a cDNA in the polycloning region of the vector with the polynucleotide either Liu or '968 for the purpose of transfecting a host cell as taught by Wood. One of ordinary skill in the art would have been motivated to make this substitution in order to express the protein encoded by the introduced DNA in a host cell to perform ligand binding and functional assays. There would have been a reasonable expectation of success for a person of ordinary skill in the art to make this invention since these techniques are widely used in the art and are highly successful. The present invention, therefore, is *prima facie* obvious over the above references in the absence of evidence to the contrary.

Art Unit: 1647

**11. Conclusion**

A. No claim is allowable

***Advisory information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (571) 272-0888. The examiner can normally be reached on Monday - Friday from 8:00 AM to 5:00 PM (Eastern time) and alternate Fridays from 8:00 AM to 5:00 PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Brenda Brumback, can be reached on (571) 272-0961.

Official papers filed by fax should be directed to (703) 872-9306. Fax draft or informal communications with the examiner should be directed to (571) 273-0888.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-0700.

Robert Landsman, Ph.D.

Patent Examiner

Group 1600

July 16, 2004

  
**ROBERT LANDSMAN**  
**PATENT EXAMINER**

## Sequence Comparison

A

ID AAY41765 standard; protein; 693 AA.

XX

DT 07-DEC-1999 (first entry)

XX

DE Human PRO1083 protein sequence.

XX

PN WO9946281-A2.

PD 16-SEP-1999.

PF 08-MAR-1999; 99WO-US005028.

XX

PA (GETH ) GENENTECH INC.

XX

PI Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;

XX

DR WPI; 1999-551358/46.

DR N-PSDB; AAZ34292.

XX

SQ Sequence 693 AA;

Query Match 100.0%; Score 3604; DB 2; Length 693;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 693; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MTPQSLQLQTTLFLLSLLFLVQGAHGRGHREDFRCSQRNQTHRSSLHYKPTPDLRISIEN 60
      |||
Db      1 MTPQSLQLQTTLFLLSLLFLVQGAHGRGHREDFRCSQRNQTHRSSLHYKPTPDLRISIEN 60

Qy      61 SEEALTVHAPFPAAHPASRSFPDPRGLYHFCLYWNRHAGRLHLLYGKRDFFLLSDKASSLL 120
      |||
Db      61 SEEALTVHAPFPAAHPASRSFPDPRGLYHFCLYWNRHAGRLHLLYGKRDFFLLSDKASSLL 120

Qy     121 CFQHQEESLAQGPPLLATSVTSWWSPQNISLPSAASFTFSFHSPHTAAHNASVDMCELK 180
      |||
Db     121 CFQHQEESLAQGPPLLATSVTSWWSPQNISLPSAASFTFSFHSPHTAAHNASVDMCELK 180

Qy     181 RDLQLLSQFLKHPQKASRRPSAAPASQQQLQSLESKLTSVRFMGDMVSFEEDRINATVWKL 240
      |||
Db     181 RDLQLLSQFLKHPQKASRRPSAAPASQQQLQSLESKLTSVRFMGDMVSFEEDRINATVWKL 240

Qy     241 QPTAGLQDLHIHSRQEEEQSEIMEYSVLLPRTLFTQRTKGRSGEAEKRLLLVDFSSQALFQ 300
      |||
Db     241 QPTAGLQDLHIHSRQEEEQSEIMEYSVLLPRTLFTQRTKGRSGEAEKRLLLVDFSSQALFQ 300

Qy     301 DKNSSQVLGEKVLGIVVQNTKVANLTPVVLTFOHQLQPKNVTLQCVFWVEDPTLSSPGH 360
      |||
Db     301 DKNSSQVLGEKVLGIVVQNTKVANLTPVVLTFOHQLQPKNVTLQCVFWVEDPTLSSPGH 360

Qy     361 WSSAGCETVRRETQTSCFCNHLTYFAVLMVSSVEVDVAVHKHYLSLLSYVGCVVVSALACL 420
      |||
Db     361 WSSAGCETVRRETQTSCFCNHLTYFAVLMVSSVEVDVAVHKHYLSLLSYVGCVVVSALACL 420

Qy     421 TIAAYLCSRVPPLPCRRKPRDYTIKVHMNLLAVFLLDTSFLLSEPVALTGSEAGCRASAI 480
      |||
Db     421 TIAAYLCSRVPPLPCRRKPRDYTIKVHMNLLAVFLLDTSFLLSEPVALTGSEAGCRASAI 480

Qy     481 FLHFSLLTCLSWMGLEGYNLYRLVVEVFGTYVPGYLLKLSAMGWGFPIFLVTLVALVDVD 540
      |||
Db     481 FLHFSLLTCLSWMGLEGYNLYRLVVEVFGTYVPGYLLKLSAMGWGFPIFLVTLVALVDVD 540

Qy     541 NYGPIILAVHRTPEGVIYPSMCWIRDSLVSYITNLGLFSLVFLFNMAMLATMVVQILRLR 600
      |||
Db     541 NYGPIILAVHRTPEGVIYPSMCWIRDSLVSYITNLGLFSLVFLFNMAMLATMVVQILRLR 600
```

Qy 601 PHTQKWSHVLTLGLSLVLGLPWALIFFSFASGTFQLVVLYLFSIITSFQGFLIFIWYWS 660  
 |||  
 Db 601 PHTQKWSHVLTLGLSLVLGLPWALIFFSFASGTFQLVVLYLFSIITSFQGFLIFIWYWS 660

Qy 661 MRLQARGGPSPLKSNSDSARLPISSGSTSSRI 693  
 |||  
 Db 661 MRLQARGGPSPLKSNSDSARLPISSGSTSSRI 693

## Sequence Comparison

AF106858  
 LOCUS AF106858 2822 bp mRNA linear PRI 17-MAY-1999  
 DEFINITION Homo sapiens G-protein-coupled receptor (GPR56) mRNA, complete cds.  
 ACCESSION AF106858  
 VERSION AF106858.1 GI:4836764  
 KEYWORDS .  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 2822)  
 AUTHORS Liu, M., Parker, R.M., Darby, K., Eyre, H.J., Copeland, N.G.,  
 Crawford, J., Gilbert, D.J., Sutherland, G.R., Jenkins, N.A. and  
 Herzog, H.  
 TITLE GPR56, a novel secretin-like human G-protein-coupled receptor gene  
 JOURNAL Genomics 55 (3), 296-305 (1999)  
 MEDLINE 99168899  
 PUBMED 10049584  
 REFERENCE 2 (bases 1 to 2822)  
 AUTHORS Herzog, H.  
 TITLE Direct Submission  
 JOURNAL Submitted (17-MAR-1999) Neurobiology, Garvan Institute, 384  
 Victoria St., Sydney, NSW 2010, Australia

### Alignment Scores:

Pred. No.:	3.89e-271	Length:	2822
Score:	3599.00	Matches:	692
Percent Similarity:	99.86%	Conservative:	0
Best Local Similarity:	99.86%	Mismatches:	1
Query Match:	99.86%	Indels:	0
DB:	9	Gaps:	0

US-09-806-537A-1 (1-693) x AF106858 (1-2822)

Qy 1 MetThrProGlnSerLeuLeuGlnThrThrLeuPheLeuLeuSerLeuLeuPheLeuVal 20  
 |||  
 Db 163 ATGACTCCCCAGTCGCTGCTGCAGACGACACTGTTCTGCTGAGTCTGCTCTTCCTGGTC 222

Qy 21 GlnGlyAlaHisGlyArgGlyHisArgGluAspPheArgPheCysSerGlnArgAsnGln 40  
 |||  
 Db 223 CAAGGTGCCACGGCAGGGGCCACAGGAAGACTTTCGCTTCTGCAGCCAGCGGAACCAG 282

Qy 41 ThrHisArgSerSerLeuHisTyrLysProThrProAspLeuArgIleSerIleGluAsn 60  
 |||  
 Db 283 ACACACAGGAGCAGCCTCCACTACAAACCCACACCAGACCTGCGCATCTCCATCGAGAAC 342

Qy 61 SerGluGluAlaLeuThrValHisAlaProPheProAlaAlaHisProAlaSerArgSer 80  
 |||  
 Db 343 TCCGAAGAGGCCCTCACAGTCCATGCCCTTTCCCTGCAGCCACCCCTGCTTCCCGATCC 402

Qy 81 PheProAspProArgGlyLeuTyrHisPheCysLeuTyrTrpAsnArgHisAlaGlyArg 100  
 |||  
 Db 403 TTCCCTGACCCAGGGGCTCTACCACTTCTGCCTCTACTGGAACCGACATGCTGGGAGA 462

Qy	101	LeuHisLeuLeuTyrGlyLysArgAspPheLeuLeuSerAspLysAlaSerSerLeuLeu	120
Db	463	TTACATCTTCTCTATGGCAAGCGTGACTTCTTGCTGAGTGACAAAGCCTCTAGCCTCCTC	522
Qy	121	CysPheGlnHisGlnGluGluSerLeuAlaGlnGlyProProLeuLeuAlaThrSerVal	140
Db	523	TGCTTCCAGCACCAGGAGGAGAGCCTGGCTCAGGGCCCCCGCTGTTAGCCACTTCTGTC	582
Qy	141	ThrSerTrpTrpSerProGlnAsnIleSerLeuProSerAlaAlaSerPheThrPheSer	160
Db	583	ACCTCCTGGTGGAGCCCTCAGAACATCAGCCTGCCAGTGCCGCCAGCTTCACCTTCTCC	642
Qy	161	PheHisSerProProHisThrAlaAlaHisAsnAlaSerValAspMetCysGluLeuLys	180
Db	643	TTCCACAGTCCTCCCCACAGGCCGCTACAATGCCTCGGTGGACATGTGCGAGCTCAAA	702
Qy	181	ArgAspLeuGlnLeuLeuSerGlnPheLeuLysHisProGlnLysAlaSerArgArgPro	200
Db	703	AGGGACCTCCAGCTGCTCAGCCAGTTCCTGAAGCATCCCCAGAAGGCCCTCAAGGAGGCC	762
Qy	201	SerAlaAlaProAlaSerGlnGlnLeuGlnSerLeuGluSerLysLeuThrSerValArg	220
Db	763	TCGGCTGCCCCGCCAGCCAGCAGTTGCAGAGCCTGGAGTCGAAACTGACCTCTGTGAGA	822
Qy	221	PheMetGlyAspMetValSerPheGluGluAspArgIleAsnAlaThrValTrpLysLeu	240
Db	823	TTCATGGGGGACATGGTGTCTTCGAGGAGGACCGGATCAACGCCACGGTATGGAAGCTC	882
Qy	241	GlnProThrAlaGlyLeuGlnAspLeuHisIleHisSerArgGlnGluGluGlnSer	260
Db	883	CAGCCACAGCCGCCTCCAGGACCTGCACATCCACTCCCGGCAGGAGGAGGAGCAGAGC	942
Qy	261	GluIleMetGluTyrSerValLeuLeuProArgThrLeuPheGlnArgThrLysGlyArg	280
Db	943	GAGATCATGGAGTACTCGGTGCTGCTGCCTCGAACACTCTTCAGAGGACGAAAGGCCGG	1002
Qy	281	SerGlyGluAlaGluLysArgLeuLeuLeuValAspPheSerSerGlnAlaLeuPheGln	300
Db	1003	AGCGGGGAGGCTGAGAAGAGACTCCTCCTGGTGGACTTCAGCAGCCAAGCCCTGTTCAG	1062
Qy	301	AspLysAsnSerSerGlnValLeuGlyGluLysValLeuGlyIleValValGlnAsnThr	320
Db	1063	GACAAGAATTCCAGCCAAGTCTGGGTGAGAAGGTCTTGGGGATTGTGGTACAGAACACC	1122
Qy	321	LysValAlaAsnLeuThrGluProValValLeuThrPheGlnHisGlnLeuGlnProLys	340
Db	1123	AAAGTAGCCAACCTCACGGAGCCCGTGGTGCTCAGTTCCAGCACCAGCTACAGCCGAAG	1182
Qy	341	AsnValThrLeuGlnCysValPheTrpValGluAspProThrLeuSerSerProGlyHis	360
Db	1183	AATGTGACTCTGCAATGTGTGTTCTGGGTGAAGACCCACATTGAGCAGCCCGGGGCAT	1242
Qy	361	TrpSerSerAlaGlyCysGluThrValArgArgGluThrGlnThrSerCysPheCysAsn	380
Db	1243	TGGAGCAGTGCTGGGTGTGAGACCGTCAGGAGAGAAACCCAAACATCCTGCTTCTGCAAC	1302
Qy	381	HisLeuThrTyrPheAlaValLeuMetValSerSerValGluValAspAlaValHisLys	400
Db	1303	CACTTGACCTACTTTGCAGTGCTGATGGTCTCCTCGGTGGAGGTGGACGCCGTGCACAAG	1362
Qy	401	HisTyrLeuSerLeuLeuSerTyrValGlyCysValValSerAlaLeuAlaCysLeuVal	420
Db	1363	CACTACCTGAGCCTCCTCTCCTACGTGGGCTGTGTGCTCTCTGCCCTGGCCTGCCTTGTG	1422

B

Qy 421 ThrIleAlaAlaTyrLeuCysSerArgValProLeuProCysArgArgLysProArgAsp 440  
| | | | |  
Db 1423 ACCATTGCCGCTACCTCTGCTCCAGGGTGCCCTGCCGTGCAGGAGGAAACCTCGGGAC 1482

Qy 441 TyrThrIleLysValHisMetAsnLeuLeuLeuAlaValPheLeuLeuAspThrSerPhe 460  
| | | | |  
Db 1483 TACACCATCAAGGTGCACATGAACCTGCTGCTGGCCGTCTCTCTGCTGGACACGAGCTTC 1542

Qy 461 LeuLeuSerGluProValAlaLeuThrGlySerGluAlaGlyCysArgAlaSerAlaIle 480  
| | | | |  
Db 1543 CTGCTCAGCGAGCCGGTGGCCCTGACAGGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATC 1602

Qy 481 PheLeuHisPheSerLeuLeuThrCysLeuSerTrpMetGlyLeuGluGlyTyrAsnLeu 500  
| | | | |  
Db 1603 TTCCTGCACCTCTCCCTGCTCACCTGCCTTTCTCTGGATGGGCCTCGAGGGGTACAACCTC 1662

Qy 501 TyrArgLeuValValGluValPheGlyThrTyrValProGlyTyrLeuLeuLysLeuSer 520  
| | | | |  
Db 1663 TACCGACTCGTGGTGGAGGTCTTTGGCACCTATGTCCCTGGCTACCTACTCAAGCTGAGC 1722

Qy 521 AlaMetGlyTrpGlyPheProIlePheLeuValThrLeuValAlaLeuValAspValAsp 540  
| | | | |  
Db 1723 GCCATGGGGCTGGGGCTTCCCCATCTTTCTGGTGACGCTGGTGGCCCTGGTGGATGTGGAC 1782

Qy 541 AsnTyrGlyProIleIleLeuAlaValHisArgThrProGluGlyValIleTyrProSer 560  
| | | | |  
Db 1783 AACTATGGCCCCATCATCTTGGCTGTGCATAGGACTCCAGAGGGCGTCATCTACCCTTCC 1842

Qy 561 MetCysTrpIleArgAspSerLeuValSerTyrIleThrAsnLeuGlyLeuPheSerLeu 580  
| | | | |  
Db 1843 ATGTGCTGGATCCGGGACTCCCTGGTCAGCTACATCACCAACCTGGGCCTCTTCAGCCTG 1902

Qy 581 ValPheLeuPheAsnMetAlaMetLeuAlaThrMetValValGlnIleLeuArgLeuArg 600  
| | | | |  
Db 1903 GTGTTTCTGTTCACATGGCCATGTAGCCACCATGGTGGTGCAGATCCTGCGGCTGCGC 1962

Qy 601 ProHisThrGlnLysTrpSerHisValLeuThrLeuLeuGlyLeuSerLeuValLeuGly 620  
| | | | |  
Db 1963 CCCCACACCCAAAAGTGGTCACATGTGCTGACACTGCTGGGCCTCAGCCTGGTCCTTGGC 2022

Qy 621 LeuProTrpAlaLeuIlePhePheSerPheAlaSerGlyThrPheGlnLeuValValLeu 640  
| | | | |  
Db 2023 CTGCCCTGGGCCTTGATCTTCTTCTCCTTTGCTTCTGGCACCTTCCAGCTTGTCGTCCTC 2082

Qy 641 TyrLeuPheSerIleIleThrSerPheGlnGlyPheLeuIlePheIleTrpTyrTrpSer 660  
| | | | |  
Db 2083 TACCTTTTCAGCATCATCACCTCCTTCCAAGGCTTCCTCATCTTCATCTGGTACTGGTCC 2142

Qy 661 MetArgLeuGlnAlaArgGlyGlyProSerProLeuLysSerAsnSerAspSerAlaArg 680  
| | | | |  
Db 2143 ATGCGGCTGCAGGCCCGGGTGGCCCTCCCTCTGAAGAGCAACTCAGACTGCGCCAGG 2202

Qy 681 LeuProIleSerSerGlySerThrSerSerSerArgIle 693  
| | | | |  
Db 2203 CTCCCCATCAGCTCGGGCAGCACCTCGTCCAGCCGCATC 2241

ID AAZ34292 standard; cDNA; 3819 BP.  
 DT 07-DEC-1999 (first entry)  
 XX  
 DE Human PRO1083 nucleotide sequence.  
 XX  
 PN WO9946281-A2.  
 XX  
 DR WPI; 1999-551358/46.  
 DR P-PSDB; AAY41765.  
 XX  
 PS Claim 2; Fig 203; 530pp; English.  
 XX  
 SQ Sequence 3819 BP; 789 A; 1221 C; 996 G; 813 T; 0 U; 0 Other;

Sequence Comparison  
 C

Alignment Scores:

Pred. No.:	4.46e-314	Length:	3819
Score:	3604.00	Matches:	693
Percent Similarity:	100.00%	Conservative:	0
Best Local Similarity:	100.00%	Mismatches:	0
Query Match:	100.00%	Indels:	0
DB:	2	Gaps:	0

US-09-806-537A-1 (1-693) x AAZ34292 (1-3819)

Qy	1	MetThrProGlnSerLeuLeuGlnThrThrLeuPheLeuLeuSerLeuLeuPheLeuVal	20
Db	214	ATGACTCCCCAGTCGCTGCTGCAGACGACACTGTTCTGCTGAGTCTGCTCTTCCTGGTC	273
Qy	21	GlnGlyAlaHisGlyArgGlyHisArgGluAspPheArgPheCysSerGlnArgAsnGln	40
Db	274	CAAGGTGCCCCACGGCAGGGGCCACAGGGAAGACTTTCGCTTCTGCAGCCAGCGGAACCAG	333
Qy	41	ThrHisArgSerSerLeuHisTyrLysProThrProAspLeuArgIleSerIleGluAsn	60
Db	334	ACACACAGGAGCAGCCTCCACTACAAACCCACACCAGACCTGCGCATCTCCATCGAGAAC	393
Qy	61	SerGluGluAlaLeuThrValHisAlaProPheProAlaAlaHisProAlaSerArgSer	80
Db	394	TCCGAAGAGGCCCTCACAGTCCATGCCCTTTCCTGCAGCCCACCCTGCTTCCCGATCC	453
Qy	81	PheProAspProArgGlyLeuTyrHisPheCysLeuTyrTrpAsnArgHisAlaGlyArg	100
Db	454	TTCCCTGACCCAGGGGCTCTACCACTTCTGCCTCTACTGGAACCGACATGTGGGAGA	513
Qy	101	LeuHisLeuLeuTyrGlyLysArgAspPheLeuLeuSerAspLysAlaSerSerLeuLeu	120
Db	514	TTACATCTTCTCTATGGCAAGCGTGACTTCTTGCTGAGTGACAAAGCCTCTAGCCTCCTC	573
Qy	121	CysPheGlnHisGlnGluGluSerLeuAlaGlnGlyProProLeuLeuAlaThrSerVal	140
Db	574	TGCTTCCAGCACCAGGAGGAGCCTGGCTCAGGGCCCCCGCTGTAGCCACTTCTGTC	633
Qy	141	ThrSerTrpTrpSerProGlnAsnIleSerLeuProSerAlaAlaSerPheThrPheSer	160
Db	634	ACCTCTGGTGGAGCCCTCAGAACATCAGCCTGCCAGTGCCGCCAGCTTCACCTTCTCC	693
Qy	161	PheHisSerProProHisThrAlaAlaHisAsnAlaSerValAspMetCysGluLeuLys	180
Db	694	TTCCACAGTCTCCCCACAGGCCGCTCACAATGCCTCGGTGGACATGTGCGAGCTCAAA	753
Qy	181	ArgAspLeuGlnLeuLeuSerGlnPheLeuLysHisProGlnLysAlaSerArgArgPro	200
Db	754	AGGGACCTCCAGCTGCTCAGCCAGTTCCTGAAGCATCCCCAGAAGGCCTCAAGGAGGCC	813



Qy	201	SerAlaAlaProAlaSerGlnGlnLeuGlnSerLeuGluSerLysLeuThrSerValArg	220
Db	814	TCGGCTGCCCGCCAGCCAGCAGTTGCAGAGCCTGGAGTCGAACTGACCTCTGTGAGA	873
Qy	221	PheMetGlyAspMetValSerPheGluGluAspArgIleAsnAlaThrValTrpLysLeu	240
Db	874	TTCATGGGGACATGGTGTCTTCGAGGAGGACCGGATCAACGCCACGGTGTGGAAGCTC	933
Qy	241	GlnProThrAlaGlyLeuGlnAspLeuHisIleHisSerArgGlnGluGluGlnSer	260
Db	934	CAGCCCACAGCCGGCCTCCAGGACCTGCACATCCACTCCCGGCAGGAGGAGGAGCAGAGC	993
Qy	261	GluIleMetGluTyrSerValLeuLeuProArgThrLeuPheGlnArgThrLysGlyArg	280
Db	994	GAGATCATGGAGTACTCGGTGCTGCTGCCTCGAACACTCTTCCAGAGGACGAAAGGCCGG	1053
Qy	281	SerGlyGluAlaGluLysArgLeuLeuLeuValAspPheSerSerGlnAlaLeuPheGln	300
Db	1054	AGCGGGGAGGCTGAGAAGAGACTCCTCTGGTGGACTTCAGCAGCCAAGCCCTGTTCCAG	1113
Qy	301	AspLysAsnSerSerGlnValLeuGlyGluLysValLeuGlyIleValValGlnAsnThr	320
Db	1114	GACAAGAATTCCAGCCAAGTCCTGGGTGAGAAGTCTTGGGGATTGTGGTACAGAACACC	1173
Qy	321	LysValAlaAsnLeuThrGluProValValLeuThrPheGlnHisGlnLeuGlnProLys	340
Db	1174	AAAGTAGCCAACCTCACGGAGCCCGTGGTGCTCACTTTCCAGCACCAGCTACAGCCGAAG	1233
Qy	341	AsnValThrLeuGlnCysValPheTrpValGluAspProThrLeuSerSerProGlyHis	360
Db	1234	AATGTGACTCTGCAATGTGTGTTCTGGGTTGAAGACCCACATTGAGCAGCCCGGGGCAT	1293
Qy	361	TrpSerSerAlaGlyCysGluThrValArgArgGluThrGlnThrSerCysPheCysAsn	380
Db	1294	TGGAGCAGTGCTGGGTGTGAGACCGTCAGGAGAGAAACCCAAACATCCTGCTTCTGCAAC	1353
Qy	381	HisLeuThrTyrPheAlaValLeuMetValSerSerValGluValAspAlaValHisLys	400
Db	1354	CACCTTGACCTACTTTGCAGTGCTGATGGTCTCCTCGGTGGAGGTGGACGCCGTGCACAAG	1413
Qy	401	HisTyrLeuSerLeuLeuSerTyrValGlyCysValValSerAlaLeuAlaCysLeuVal	420
Db	1414	CACTACCTGAGCCTCCTCTCTACGTGGGCTGTGTCTCTGCGCTGGCCTGCCTTGTC	1473
Qy	421	ThrIleAlaAlaTyrLeuCysSerArgValProLeuProCysArgArgLysProArgAsp	440
Db	1474	ACCATTGCCGCCTACCTCTGTCTCCAGGGTGCCCTGCGGTGCAGGAGGAAACCTCGGGAC	1533
Qy	441	TyrThrIleLysValHisMetAsnLeuLeuLeuAlaValPheLeuLeuAspThrSerPhe	460
Db	1534	TACACCATCAAGGTGCACATGAACCTGCTGCTGGCCGTCTTCTGCTGGACACGAGCTTC	1593
Qy	461	LeuLeuSerGluProValAlaLeuThrGlySerGluAlaGlyCysArgAlaSerAlaIle	480
Db	1594	CTGCTCAGCGAGCCGGTGGCCCTGACAGGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATC	1653
Qy	481	PheLeuHisPheSerLeuLeuThrCysLeuSerTrpMetGlyLeuGluGlyTyrAsnLeu	500
Db	1654	TTCTGCACTTCTCCCTGCTCACCTGCCTTTCTGGATGGGCCTCGAGGGGTACAACCTC	1713
Qy	501	TyrArgLeuValValGluValPheGlyThrTyrValProGlyTyrLeuLeuLysLeuSer	520
Db	1714	TACCGACTCGTGGTGGAGGTCTTTGGCACCTATGTCCCTGGCTACCTACTCAAGCTGAGC	1773



Qy	239	CAAACCCACACCAGACCTGCGCATCTCCATCGAGAACTCCGAAGAGGCCCTCACAGTCCA	298
Db	357	CAAACCCACACCAGACCTGCGCATCTCCATCGAGAACTCCGAAGAGGCCCTCACAGTCCA	416
Qy	299	TGCCCCCTTTCCCTGCAGCCACCCCTGCTTCCCGATCCTTCCCTGACCCAGGGGCCTCTA	358
Db	417	TGCCCCCTTTCCCTGCAGCCACCCCTGCTTCCCGATCCTTCCCTGACCCAGGGGCCTCTA	476
Qy	359	CCACTTCTGCCTCTACTGGAACCGACATGCTGGGAGATTACATCTTCTCTATGGCAAGCG	418
Db	477	CCACTTCTGCCTCTACTGGAACCGACATGCTGGGAGATTACATCTTCTCTATGGCAAGCG	536
Qy	419	TGACTTCTTGCTGAGTGACAAAGCCTCTAGCCTCCTCTGCTTCCAGCACCAGGAGGAGAG	478
Db	537	TGACTTCTTGCTGAGTGACAAAGCCTCTAGCCTCCTCTGCTTCCAGCACCAGGAGGAGAG	596
Qy	479	CCTGGCTCAGGGCCCCCGCTGTTAGCCACTTCTGTACCTCCTGGTGGAGCCCTCAGAA	538
Db	597	CCTGGCTCAGGGCCCCCGCTGTTAGCCACTTCTGTACCTCCTGGTGGAGCCCTCAGAA	656
Qy	539	CATCAGCCTGCCCAGTGCCGCCAGCTTACCTTCTCCTTCCACAGTCTCCCCACACGGC	598
Db	657	CATCAGCCTGCCCAGTGCCGCCAGCTTACCTTCTCCTTCCACAGTCTCCCCACACGGC	716
Qy	599	CGCTCACAAATGCCTCGGTGGACATGTGCGAGCTCAAAGGGACCTCCAGCTGCTCAGCCA	658
Db	717	CGCTCACAAATGCCTCGGTGGACATGTGCGAGCTCAAAGGGACCTCCAGCTGCTCAGCCA	776
Qy	659	GTTCTGAAGCATCCCCAGAAGGCCTCAAGGAGGCCCTCGGCTGCCCCCGCCAGCCAGCA	718
Db	777	GTTCTGAAGCATCCCCAGAAGGCCTCAAGGAGGCCCTCGGCTGCCCCCGCCAGCCAGCA	836
Qy	719	GTTGCAGAGCCTGGAGTCGAAACTGACCTCTGTGAGATTATGGGGGACATGGTGTCTTT	778
Db	837	GTTGCAGAGCCTGGAGTCGAAACTGACCTCTGTGAGATTATGGGGGACATGGTGTCTTT	896
Qy	779	CGAGGAGGACCGGATCAACGCCACGGTGTGGAAGCTCCAGCCCACAGCCGGCCTCCAGGA	838
Db	897	CGAGGAGGACCGGATCAACGCCACGGTGTGGAAGCTCCAGCCCACAGCCGGCCTCCAGGA	956
Qy	839	CCTGCACATCCACTCCCGGCAGGAGGAGCAGAGCGAGATCATGGAGTACTCGGTGCT	898
Db	957	CCTGCACATCCACTCCCGGCAGGAGGAGCAGAGCGAGATCATGGAGTACTCGGTGCT	1016
Qy	899	GCTGCCTCGAACACTCTTCCAGAGGACGAAAGGCCGGAGCGGGGAGGCTGAGAAGAGACT	958
Db	1017	GCTGCCTCGAACACTCTTCCAGAGGACGAAAGGCCGGAGCGGGGAGGCTGAGAAGAGACT	1076
Qy	959	CCTCCTGGTGGACTTCAGCAGCCAAGCCCTGTTCCAGGACAAGAATTCCAGCCAAGTCCT	1018
Db	1077	CCTCCTGGTGGACTTCAGCAGCCAAGCCCTGTTCCAGGACAAGAATTCCAGCCAAGTCCT	1136
Qy	1019	GGGTGAGAAGGTCTTGGGGATTGTGGTACAGAACACCAAAGTAGCCAACCTCACGGAGCC	1078
Db	1137	GGGTGAGAAGGTCTTGGGGATTGTGGTACAGAACACCAAAGTAGCCAACCTCACGGAGCC	1196
Qy	1079	CGTGGTGCTCACCTTCCAGCACCAGCTACAGCCGAAGAATGTGACTCTGCAATGTGTGTT	1138
Db	1197	CGTGGTGCTCACCTTCCAGCACCAGCTACAGCCGAAGAATGTGACTCTGCAATGTGTGTT	1256
Qy	1139	CTGGGTTGAAGACCCACATTGAGCAGCCCGGGGCATTGGAGCAGTGCTGGGTGTGAGAC	1198
Db	1257	CTGGGTTGAAGACCCACATTGAGCAGCCCGGGGCATTGGAGCAGTGCTGGGTGTGAGAC	1316

Qy	1199	CGTCAGGAGAGAAAACCCAAACATCCTGCTTCTGCAACCACTTGACCTACTTTGCAGTGTCT	1258
Db	1317	CGTCAGGAGAGAAAACCCAAACATCCTGCTTCTGCAACCACTTGACCTACTTTGCAGTGTCT	1376
Qy	1259	GATGGTCTCCTCGGTGGAGGTGGACGCCGTGCACAAGCACTACCTGAGCCTCCTCTCCTA	1318
Db	1377	GATGGTCTCCTCGGTGGAGGTGGACGCCGTGCACAAGCACTACCTGAGCCTCCTCTCCTA	1436
Qy	1319	CGTGGGCTGTGTCTGCTCTCTGCCCTGGCCTGCCTTGTACCATTGCCGCCTACCTCTGCTC	1378
Db	1437	CGTGGGCTGTGTCTGCTCTCTGCCCTGGCCTGCCTTGTACCATTGCCGCCTACCTCTGCTC	1496
Qy	1379	CAGGGTGCCCCCTGCCGTGCAGGAGGAAACCTCGGGACTACACCATCAAGGTGCACATGAA	1438
Db	1497	CAGGGTGCCCCCTGCCGTGCAGGAGGAAACCTCGGGACTACACCATCAAGGTGCACATGAA	1556
Qy	1439	CCTGCTGCTGGCCGTCTTCCTGCTGGACACGAGCTTCCTGCTCAGCGAGCCGGTGGCCCT	1498
Db	1557	CCTGCTGCTGGCCGTCTTCCTGCTGGACACGAGCTTCCTGCTCAGCGAGCCGGTGGCCCT	1616
Qy	1499	GACAGGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATCTTCCTGCACTTCTCCCTGCTCAC	1558
Db	1617	GACAGGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATCTTCCTGCACTTCTCCCTGCTCAC	1676
Qy	1559	CTGCCTTTCTGGATGGGCCCTCGAGGGGTACAACCTCTACCGACTCGTGGTGGAGGTCTT	1618
Db	1677	CTGCCTTTCTGGATGGGCCCTCGAGGGGTACAACCTCTACCGACTCGTGGTGGAGGTCTT	1736
Qy	1619	TGGCACCTATGTCCCTGGCTACCTACTCAAGCTGAGCGCCATGGGCTGGGGCTTCCCCAT	1678
Db	1737	TGGCACCTATGTCCCTGGCTACCTACTCAAGCTGAGCGCCATGGGCTGGGGCTTCCCCAT	1796
Qy	1679	CTTTCTGGTGACGCTGGTGGCCCTGGTGGATGTGGACAACATATGGCCCCATCATCTTGGC	1738
Db	1797	CTTTCTGGTGACGCTGGTGGCCCTGGTGGATGTGGACAACATATGGCCCCATCATCTTGGC	1856
Qy	1739	TGTGCATAGGACTCCAGAGGGCGTCATCTACCCCTCCATGTGCTGGATCCGGGACTCCCT	1798
Db	1857	TGTGCATAGGACTCCAGAGGGCGTCATCTACCCCTCCATGTGCTGGATCCGGGACTCCCT	1916
Qy	1799	GGTCAGCTACATCACCAACCTGGGCCTCTTCAGCCTGGTGTCTCTGTTCAACATGGCCAT	1858
Db	1917	GGTCAGCTACATCACCAACCTGGGCCTCTTCAGCCTGGTGTCTCTGTTCAACATGGCCAT	1976
Qy	1859	GCTAGCCACCATGGTGGTGCAGATCCTGCGGCTGCGCCCCCACACCCAAAAGTGGTCACA	1918
Db	1977	GCTAGCCACCATGGTGGTGCAGATCCTGCGGCTGCGCCCCCACACCCAAAAGTGGTCACA	2036
Qy	1919	TGTGCTGACACTGCTGGGCCTCAGCCTGGTCCTTGGCCTGCCCTGGGCCTTGATCTTCTT	1978
Db	2037	TGTGCTGACACTGCTGGGCCTCAGCCTGGTCCTTGGCCTGCCCTGGGCCTTGATCTTCTT	2096
Qy	1979	CTCCTTTGCTTCTGGCACCTTCCAGCTTGTCTCCTCTACCTTTTCAGCATCATCACCTC	2038
Db	2097	CTCCTTTGCTTCTGGCACCTTCCAGCTTGTCTCCTCTACCTTTTCAGCATCATCACCTC	2156
Qy	2039	CTTCCAAGGCTTCCTCATCTTCATCTGGTACTGGTCCATGCGGCTGCAGGCCCGGGTGG	2098
Db	2157	CTTCCAAGGCTTCCTCATCTTCATCTGGTACTGGTCCATGCGGCTGCAGGCCCGGGTGG	2216
Qy	2099	CCCTCCCTCTGAAGAGCAACTCAGACAGCGCCAGGCTCCCCATCAGCTCGGGCAGCAC	2158
Db	2217	CCCTCCCTCTGAAGAGCAACTCAGACAGCGCCAGGCTCCCCATCAGCTCGGGCAGCAC	2276

D

Qy	2159	CTCGTCCAGCCGCATCTAGGCCTCCAGCCCACCTGCCCATGTGATGAAGCAGAGATGCGG	2218
Db	2277	CTCGTCCAGCCGCATCTAGGCCTCCAGCCCACCTGCCCATGTGATGAAGCAGAGATGCGG	2336
Qy	2219	CCTCGTCGCACACTGCCTGTGGCCCCGAGCCCGGCCAGCCCCAGGCCAGTCAGCCGCA	2278
Db	2337	CCTCGTCGCACACTGCCTGTGGCCCCGAGCCAGGCCAGCCCCAGGCCAGTCAGCCGCA	2396
Qy	2279	GACTTTGGAAAGCCCAACGACCATGGAGAGATGGGCCGTTGCCATGGTGGACGGACTCCC	2338
Db	2397	GACTTTGGAAAGCCCAACGACCATGGAGAGATGGGCCGTTGCCATGGTGGACGGACTCCC	2456
Qy	2339	GGGCTGGGCTTTTGAATTGGCCTTGGGGACTACTCGGCTCTCACTCAGCTCCACGGGAC	2398
Db	2457	GGGCTGGGCTTTTGAATTGGCCTTGGGGACTACTCGGCTCTCACTCAGCTCCACGGGAC	2516
Qy	2399	TCAGAAGTGCGCCGCCATGCTGCCTAGGGTACTGTCCCCACATCTGTCCCAACCCAGCTG	2458
Db	2517	TCAGAAGTGCGCCGCCATGCTGCCTAGGGTACTGTCCCCACATCTGTCCCAACCCAGCTG	2576
Qy	2459	GAGGCCTGGTCTCTCCTTATAACCCCTGGGCCCAGCCCTCATTGCTGGGGGCCAGGCCTT	2518
Db	2577	GAGGCCTGGTCTCTCCTTACAACCCCTGGGCCCAGCCCTCATTGCTGGGGGCCAGGCCTT	2636
Qy	2519	GGATCTTGAGGGTCTGGCACATCCTTAATCCTGTGCCCCCTGCCTGGGACAGAAATGTGGC	2578
Db	2637	GGATCTTGAGGGTCTGGCACATCCTTAATCCTGTGCCCCCTGCCTGGGACAGAAATGTGGC	2696
Qy	2579	TCCAGTTGCTCTGTCTCTCGTGGTCACCCTGAGGGCACTCTGCATCCTCTGTCAATTTAA	2638
Db	2697	TCCAGTTGCTCTGTCTCTCGTGGTCACCCTGAGGGCACTCTGCATCCTCTGTCAATTTAA	2756
Qy	2639	CCTCAGGTGGCACCCAGGGCGAATGGGGCCCAGGGCAGACCTTCAGGGCCAGAGCCCTGG	2698
Db	2757	CCTCAGGTGGCACCCAGGGCGAATGGGGCCCAGGGCAGACCTTCAGGGCCAGAGCCCTGG	2816
Qy	2699	CGGAGGAGAGGCCCTTTGCCAGGAGCACAGCAGCAGCTCGCCTACCTCTGAGCCCAGGCC	2758
Db	2817	CGGAGGAGAGGCCCTTTGCCAGGAGCACAGCAGCAGCTCGCCTACCTCTGAGCCCAGGCC	2876
Qy	2759	CCCTCCCTCCCTCAGCCCCCAGTCCCTCCCTCCATCTTCCCTGGGGTTCTCCTCCTCTCC	2818
Db	2877	CCCTCCCTCCCTCAGCCCCCAGTCCCTCCCTCCATCTTCCCTGGGGTTCTCCTCCTCTCC	2936
Qy	2819	CAGGCCTCCTTGCTCCTTCGTTACAGCTGGGGGTCCCCGATTCCAATGCTGTTTTTTG	2878
Db	2937	CAGGCCTCCTTGCTCCTTCGTTACAGCTGGGGGTCCCCGATTCCAATGCTGTTTTTTG	2996
Qy	2879	GGGAGTGGTTTTCCAGGAGCTGCCTGGTGTCTGCTGTAAATGTTTGTCTACTGCACAAGCC	2938
Db	2997	GGGAGTGGTTTTCCAGGAGCTGCCTGGTGTCTGCTGTAAATGTTTGTCTACTGCACAAGCC	3056
Qy	2939	TCGGCCTGCCCCTGAGCCAGGCTCGGTACCGATGCGTGGGCTGGGCTAGGTCCCTCTGTC	2998
Db	3057	TCGGCCTGCCCCTGAGCCAGGCTCGGTACCGATGCGTGGGCTGGGCTAGGTCCCTCTGTC	3116
Qy	2999	CATCTGGGCCTTTGTATGAGCTGCATTGCCCTTGCTCACCCCTGACCAAGCACACGCCTCA	3058
Db	3117	CATCTGGGCCTTTGTATGAGCTGCATTGCCCTTGCTCACCCCTGACCAAGCACACGCCTCA	3176
Qy	3059	GAGGGGCCCTCAGCCTCTCCTGAAGCCCTCTTGTGGCAAGAACTGTGGACCATGCCAGTC	3118
Db	3177	GAGGGGCCCTCAGCCTCTCCTGAAGCCCTCTTGTGGCAAGAACTGTGGACCATGCCAGTC	3236

Qy 3119 CCGTCTGGTTTCCATCCCACCACTCCAAGGACTGAGACTGACCTCCTCTGGTGACACTGG 3178  
 |||  
 Db 3237 CCGTCTGGTTTCCATCCCACCACTCCAAGGACTGAGACTGACCTCCTCTGGTGACACTGG 3296  
 |||  
 Qy 3179 CCTAGAGCCTGACACTCTCCTAAGAGGTTCTCTCCAAGCCCCAAATAGCTCCAGGCGCC 3238  
 |||  
 Db 3297 CCTAGAGCCTGACACTCTCCTAAGAGGTTCTCTCCAAGCCCCAAATAGCTCCAGGCGCC 3356  
 |||  
 Qy 3239 CTCGGCCGCCCATCATGGTTAATTCTGTCCAACAAACACACACGGGTAGATTGCTGGCCT 3298  
 |||  
 Db 3357 CTCGGCCGCCCATCATGGTTAATTCTGTCCAACAAACACACACGGGTAGATTGCTGGCCT 3416  
 |||  
 Qy 3299 GTTGTAGGTGGTAGGGACACAGATGACCGACCTGGTCACTCCTCCTGCCAACATTTCAGTC 3358  
 |||  
 Db 3417 GTTGTAGGTGGTAGGGACACAGATGACCGACCTGGTCACTCCTCCTGCCAACATTTCAGTC 3476  
 |||  
 Qy 3359 TGGTATGTGAGGCGTGCCTGAAGCAAGAACTCCTGGAGCTACAGGGACAGGGAGCCATCA 3418  
 |||  
 Db 3477 TGGTATGTGAGGCGTGCCTGAAGCAAGAACTCCTGGAGCTACAGGGACAGGGAGCCATCA 3536  
 |||  
 Qy 3419 TTCCTGCCTGGGAATCCTGGAAGACTTCCTGCAGGAGTCAGCGTTCAATCTTGACCTTGA 3478  
 |||  
 Db 3537 TTCCTGCCTGGGAATCCTGGAAGACTTCCTGCAGGAGTCAGCGTTCAATCTTGACCTTGA 3596  
 |||  
 Qy 3479 AGATGGGAAGGATGTTCTTTTTACGTACCAATTCTTTTGTCTTTTGATATTAAAAAGAAG 3538  
 |||  
 Db 3597 AGATGGGAAGGATGTTCTTTTTACGTACCAATTCTTTTGTCTTTTGATATTAAAAAGAAG 3656  
 |||  
 Qy 3539 TACATGTTTCATTGTAGAGAATTTGGAAACTGTAGAAGAGAATCAAGAAGAAAAATAAAAA 3598  
 |||  
 Db 3657 TACATGTTTCATTGTAGAGAATTTGGAAACTGTAGAAGAGAATCAAGAAGAAAAATAAAAA 3716  
 |||  
 Qy 3599 TCAGCTGTTGTAATCACCTAGCAAAAAAAAAAAAA 3632  
 |||  
 Db 3717 TCAGCTGTTGTAATCGCCTAGCAAAAAAAAAAAAA 3750  
 |||

; Sequence 78, Application US/09276531  
 ; Patent No. 6183968  
 ; GENERAL INFORMATION:  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/276,531  
 ; FILING DATE: Herewith  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 60/079,677  
 ; FILING DATE: March 27, 1998  
 ; CLASSIFICATION:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Lynn E. Murry, Ph.D.  
 ; REGISTRATION NUMBER: 42,918  
 ; REFERENCE/DOCKET NUMBER: PA-0008 US  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (650) 855-0555  
 ; TELEFAX: (650) 845-4166  
 ; INFORMATION FOR SEQ ID NO: 78:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 3090 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; IMMEDIATE SOURCE:

Sequence Comparison

E

Qy	601	CTCACAATGCCTCGGTGGACATGTGCGAGACTCAAAGGGACCTCCAGCTGCTCAGCCAGT	660
Db	36	CGCACAAATNCCTCGGTGGACATGTGCGAGACTCAAAGGGACCTCCNGTGTCTCAGCCAGT	95
Qy	661	TCCTGAAGCATCCCCAGAAGGCCTCAAGGAGGCCCTCGGCTGCCCCGCCAGCCAGCAGT	720
Db	96	TCCTGAAGCATCCCCAGAAGGCCTCAAGGAGGCCCTCGGCTGCCCCGCCAGCCAGCAGT	155
Qy	721	TGCAGAGCCTGGAGTCGAAACTGACCTCTGTGAGATTATGGGGGACATGGTGTCTTCG	780
Db	156	TGCAGAGCCTGGAGTCGAAACTGACCTCTGTGAGATTATGGGGGACATGGTGTCTTCG	215
Qy	781	AGGAGGACCGGATCAACGCCACGGTGTGGAAGCTCCAGCCACAGCCGGCCTCCAGGACC	840
Db	216	AGGAGGACCGGATCAACGCCACGGTGTGGAAGCTCCAGCCACAGCCGGCCTCCAGGACC	275
Qy	841	TGCACATCCACTCCCGGCAGGAGGAGGAGCAGAGCGAGATCATGGAGTACTCGGTGCTGC	900
Db	276	TGCACATCCACTCCCGGCAGGAGGAGGAGCAGAGCGAGATCATGGAGTACTCGGTGCTGC	335
Qy	901	TGCCTCGAACACTCTTCCAGAGGACGAAAGGCCGAGCGGGAGGCTGAGAAGAGACTCC	960
Db	336	TGCCTCGAACACTCTTCCAGAGGACGAAAGGCCGAGCGGGAGGCTGAGAAGAGACTCC	395
Qy	961	TCCTGGTGGACTTCAGCAGCCAAGCCCTGTTCCAGGACAAGAATTCCAGCCAAGTCCTGG	1020
Db	396	TCCTGGTGGACTTCAGCAGCCAAGCCCTGTTCCAGGACAAGAATTCCAGCCAAGTCCTGG	455
Qy	1021	GTGAGAAGGTCTTGGGGATTGTGGTACAGAACACCAAAGTAGCCAACCTCACGGAGCCCG	1080
Db	456	GTGAGAAGGTCTTGGGGATTGTGGTACAGAACACCAAAGTAGCCAACCTCACGGAGCCCG	515
Qy	1081	TGGTGCTCACCTTCCAGCACCAGCTACAGCCGAAGAATGTGACTCTGCAATGTGTGTTCT	1140
Db	516	TGGTGCTCACCTTCCAGCACCAGCTACAGCCGAAGAATGTGACTCTGCAATGTGTGTTCT	575
Qy	1141	GGGTTGAAGACCCACATTGAGCAGCCCGGGGCATTGGAGCAGTGTGGGTGTGAGACCG	1200
Db	576	GGGTTGAAGACCCACATTGAGCAGCCCGGGGCATTGGAGCAGTGTGGGTGTGAGACCG	635
Qy	1201	TCAGGAGAGAAACCCAAACATCCTGCTTCTGCAACCATTGACCTACTTTGCAGTGCTGA	1260
Db	636	TCAGGAGAGAAACCCAAACATCCTGCTTCTGCAACCATTGACCTACTTTGCAGTGCTGA	695
Qy	1261	TGGTCTCCTCGGTGGAGGTGGACGCCGTGCACAAGCACTACCTGAGCCTCCTCTCCTACG	1320
Db	696	TGGTCTCCTCGGTGGAGGTGGACGCCGTGCACAAGCACTACCTGAGCCTCCTCTCCTACG	755
Qy	1321	TGGGCTGTGTCTCTCTGCCCTGGCCTGCCTTGTCAACATTGCCGCCTACCTCTGCTCCA	1380
Db	756	TGGGCTGTGTCTCTCTGCCCTGGCCTGCCTTGTCAACATTGCCGCCTACCTCTGCTCCA	815
Qy	1381	GGGTGCCCTGCCGTGCAGGAGGAAACCTCGGGACTACACCATCAAGGTGCACATGAACC	1440
Db	816	GGGTGCCCTGCCGTGCAGGAGGAAACCTCGGGACTACACCATCAAGGTGCACATGAACC	875

2

Qy 1441 TGCTGCTGGCCGCTCTTCCTGCTGGACACGAGCTTCCTGCTCAGCGAGCCGGTGGCCCTGA 1500  
| | | | |  
Db 876 TGCTGCTGGCCGCTCTTCCTGCTGGACACGAGCTTCCTGCTCAGCGAGCCGGTGGCCCTGA 935  
| | | | |  
Qy 1501 CAGGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATCTTCCTGCACCTCTCCCTGCTCACCT 1560  
| | | | |  
Db 936 CAGGCTCTGAGGCTGGCTGCCGAGCCAGTGCCATCTTCCTGCACCTCTCCCTGCTCACCT 995  
| | | | |  
Qy 1561 GCCTTTCTGATGGGCTCGAGGGGTACAACCTCTACCGACTCGTGGTGGAGGTCTTTG 1620  
| | | | |  
Db 996 GCCTTTCTGATGGGCTCGAGGGGTACAACCTCTACCGACTCGTGGTGGAGGTCTTTG 1055  
| | | | |  
Qy 1621 GCACCTATGTCCCTGGCTACCTACTCAAGCTGAGCGCCATGGGCTGGGGCTTCCCCATCT 1680  
| | | | |  
Db 1056 GCACCTATGTCCCTGGCTACCTACTCAAGCTGAGCGCCATGGGCTGGGGCTTCCCCATCT 1115  
| | | | |  
Qy 1681 TTCTGGTGACGCTGGTGGCCCTGGTGGATGTGGACAACTATGGCCCCATCATCTTGGCTG 1740  
| | | | |  
Db 1116 TTCTGGTGACGCTGGTGGCCCTGGTGGATGTGGACAACTATGGCCCCATCATCTTGGCTG 1175  
| | | | |  
Qy 1741 TGCATAGGACTCCAGAGGGCGTCATCTACCCTTCCATGTGCTGGATCCGGGACTCCCTGG 1800  
| | | | |  
Db 1176 TGCATAGGACTCCAGAGGGCGTCATCTACCCTTCCATGTGCTGGATCCGGGACTCCCTGG 1235  
| | | | |  
Qy 1801 TCAGCTACATCACCAACCTGGGCCTCTTCAGCCTGGTGTTCCTGTTCAACAT-GGCCATG 1859  
| | | | |  
Db 1236 TCAGCTACATCACCAACCTGGGCCTCTTCAGCCTGGTGTTCCTGTTCAACATGGGCCATG 1295  
| | | | |  
Qy 1860 CTAGCCACCATGGTGGTGCAGATCCTGCGGCTGCGCCCCACACCCAAAAGT-GGTCACA 1918  
| | | | |  
Db 1296 CTAGCCACCATGGTGGTGCAGATCCTGCGGCTGCGCCCCACACCCAAAAGTGGGTGACA 1355  
| | | | |  
Qy 1919 TGTGCTGACACTGCTGGGCCTCAGCCTGGTCTTGGCCTGCCCT-GGGCCTGATCTTCT 1977  
| | | | |  
Db 1356 TGTGCTGACACTGCTGGGCCTCAGCCTGGTCTTGGCCTGCCCTGGGCCTGATCTTCT 1415  
| | | | |  
Qy 1978 TCTCCTTTGCTTCTGGCACCTTCCAGCTTGTCGTCTCTACCTTTTCAGCATCATCACCT 2037  
| | | | |  
Db 1416 TCTCCTTTGCTTCTGGCACCTTCCAGCTTGTCGTCTCTACCTTTTCAGCATCATCACCT 1475  
| | | | |  
Qy 2038 CCTTCCAAGGCTTCCTCATCTTCATCTGGTACTGGTCCATGCGGCTGCAGGCCCCGGGGTG 2097  
| | | | |  
Db 1476 CCTTCCAAGGCTTCCTCATCTTCATCTGGTACTGGTCCATGCGGCTGCAGGCCCCGGGGTG 1535  
| | | | |  
Qy 2098 GCCCCCTCCCCTCTGAAGAGCAACTCAGACAGCGCCAGGCTCCCCATCAGCTCGGGCAGCA 2157  
| | | | |  
Db 1536 GCCCCCTCCCCTCTGAAGAGCAACTCAGACAGCGCCAGGCTCCCCATCAGCTCGGGCAGCA 1595  
| | | | |  
Qy 2158 CCTCGTCCAGCCGCATCTAGGCCTCCAGCCCACCTGCCCATGTGATGAAGCAGAGATGCG 2217  
| | | | |  
Db 1596 CCTCGTCCAGCCGCATCTAGGCCTCCAGCCCACCTGCCCATGTGATGAAGCAGAGATGCG 1655  
| | | | |  
Qy 2218 GCCTCGTCGCACACTGCCTGTGGCCCCCGAGCCCCGAGCCCCAGGCCAGTCAGCCGC 2277  
| | | | |  
Db 1656 GCCTCGTCGCACACTGCCTGTGGCCCCCGAGGCCAGGCCAGCCCCAGGCCAGTCAGCCGC 1715  
| | | | |  
Qy 2278 AGACTTTGGAAAGCCCAACGACCATGGAGAGATGGGCCGTTGCCATGGTGGAC-GGACTC 2336  
| | | | |  
Db 1716 AGACTTTGGAAAGCCCAACGACCATGGAGAGATGGGCCGTTGCCATGGTGGACGGGACTC 1775  
| | | | |  
Qy 2337 CCGGGCTGGGCTTTTGAATTGGCCTTGGGGACTACTCGGCTCTCACTCAGTCCCACGGG 2396  
| | | | |  
Db 1776 CCGGGCTGGGCTTTTGAATTGGCCTTGGGGACTACTCGGCTCTCACTCAGTCCCACGGG 1835  
| | | | |



Qy 2397 ACTCAGAAGTGCGCCGCCATGCTGCCTAGGGTACTGTCCCCACATCTGTCCCAACCCAGC 2456  
 |||  
 Db 1836 ACTCAGAAGTGCGCCGCCATGCTGCCTAGGGTACTGTCCCCACATCTGTCCCAACCCAGC 1895

Qy 2457 TGGAGGCCTGGTCTCTCCTTATAACCCCT-GGGCCCAGCCCTCATTGCTGGGGGCCAGGC 2515  
 |||  
 Db 1896 TGGAGGCCTGGTCTCTCCTTATAACCCCTGGGGCCCAGCCCTCATTGCTGGGGGCCAGGC 1955

Qy 2516 CTTGGATCTTGAGGGTCTGGCACATCCTTAATCCTGTGCCCTGCCTGGGACAGAAATGT 2575  
 |||  
 Db 1956 CTTGGATCTTGAGGGTCTGGCACATCCTTAATCCTGTGCCCTGCCTGGGACAGAAATGT 2015

Qy 2576 GGCTCCAGTTGCTCTGTCTCTCGTGGTCACCCCTGAGGGCACTCTGCATCCTCTGTCAATTT 2635  
 |||  
 Db 2016 GGCTCCAGTTGCTCTGTCTCTCGTGGTCACCCCTGAGGGCACTCTGCATCCTCTGTCAATTT 2075

Qy 2636 TAACCTCAGGTGGCACCCAGGGCGAATGGGGCCCAGGGCAGACCTTCAGGGCCAGAGCCC 2695  
 |||  
 Db 2076 TAACCTCAGGTGGCACCCAGGGCGAATGGGGCCCAGGGCAGACCTTCAGGGCCAGAGCCC 2135

Qy 2696 TGGCGGAGGAGAGGCCCTTTGCCAGGAGCACAGCAGCTCGCCTACCTCTGAGCCCAG 2755  
 |||  
 Db 2136 TGGCGGAGGAGAGGCCCTTTGCCAGGAGCACAGCAGCTCGCCTACCTCTGAGCCCAG 2195

Qy 2756 GCCCCCTCCCTCCCTCAGCCCCCAGTCCTCCCTCCATCTTCCCTGGGGTTCTCCTCCTC 2815  
 |||  
 Db 2196 GCCCCCTCCCTCCCTCAGCCCCCAGTCCTCCCTCCATCTTCCCTGGGGTTCTCCTCCTC 2255

Qy 2816 TCCCAGGGCCTCCTTGCTCCTTCGTTACAGCT-GGGGGTCCCGATTCCAATGCTGTTT 2874  
 |||  
 Db 2256 TCCCAGGGCCTCCTTGCTCCTTCGTTACAGCTGGGGGTCCCGATTCCAATGCTGTTT 2315

Qy 2875 TTTGGGGAGTGGTTTCCAGGAGCTGCCTGGTGTCTGCTGTAAATGTTGTCTACTGCACA 2934  
 |||  
 Db 2316 TTTGGGGAGTGGTTTCCAGGAGCTGCCTGGTGTCTGCTGTAAATGTTGTCTACTGCACA 2375

Qy 2935 AGCCTCGGCCTGCCCCCT-GAGCCAGGCTCGGTACCGATGCGTGGGCTGGGCTAGGTCCCT 2993  
 |||  
 Db 2376 AGCCTCGGCCTGCCCCCTGGAGCCAGGCTCGGTACCGATGCGTGGGCTGGGCTAGGTCCCT 2435

Qy 2994 CTGTCCATCTGGGCCCTTGTATGAGCTGCATTGCCCTTGCTCACCCCTGACCAAGCACACG 3053  
 |||  
 Db 2436 CTGTCCATCTGGGCCCTTGTATGAGCTGCATTGCCCTTGCTCACCCCTGACCAAGCACACG 2495

Qy 3054 CCTCAGAGGGGCCCTCAGCCTCTCCTGAAGCCCTCTTGTGGCAAGAACTGTGGACCATGC 3113  
 |||  
 Db 2496 CCTCAGAGGGGCCCTCAGCCTCTCCTGAAGCCCTCTTGTGGCAAGAACTGTGGACCATGC 2555

Qy 3114 CAGTCCCGTCTGGTTTCCATCCCACCACTCCAAGGACTGAGACTGACCTCCTCTGGTGAC 3173  
 |||  
 Db 2556 CAGTCCCGTCTGGTTTCCATCCCACCACTCCAAGGACTGAGACTGACCTCCTCTGGTGAC 2615

Qy 3174 ACTGGCCTAGAGCCTGACACTCTCCTAAGAGGTTCTCTCCAAGCCCCAAATAGCTCCAG 3233  
 |||  
 Db 2616 ACTGGCCTAGGGCCTGACACTCTCCTAAGAGGTTCTCTCCAAGCCCCAAATAGCTCCAG 2675

Qy 3234 GCGCCCTCGGCCGCCCATCATGGTTAATTCTGTCCAACAAACACACGGGTAGATTGCT 3293  
 |||  
 Db 2676 GCGCCCTCGGCCGCCCATCATGGTTAATTCTGTCCAACAAACACACGGGTAGATTGCT 2735

Qy 3294 GGCCTGTTGTAGGTGGTAGGGACACAGATGACCGACCTGGTCACTCCTCCTGCCAACATT 3353  
 |||  
 Db 2736 GGCCTGTTGTAGGTGGTAGGGACACAGATGACCGACCTGGTCACTCCTCCTGCCAACATT 2795

2

Qy 3354 CAGTCTGGTATGTGAGGCGTGCGTGAAGCAAGAACTCCTGGAGCTACAGGGACAGGGAGC 3413  
|||||  
Db 2796 CAGTCTGGTATGTGAGGCGTGCGTGAAGCAAGAACTCCTGGAGCTACAGGGACAGGGAGC 2855  
  
Qy 3414 CATCATTCCTGCCTGGGAATCCTGGAAGACTTCCTGCAGGAGTCAGCGTTCAATCTTGAC 3473  
|||||  
Db 2856 CATCATTCCTGCCTGGGAATCCTGGAAGACTTCCTGCAGGAGTCAGCGTTCAATCTTGAC 2915  
  
Qy 3474 CTTGAAGATGGGAAGGATGTTCTTTTACGTACCAATTCTTTGTCTTTTGATATTAAAA 3533  
|||||  
Db 2916 CTTGAAGATGGGAAGGATGTTCTTTTACGTACCAATTCTTTGTCTTTTGATATTAAAA 2975  
  
Qy 3534 AGAAGTACATGTTTCATTGTAGAGAATTTGGAACTGTAGAAGAGAATCAAGAAGAAAAAT 3593  
|||||  
Db 2976 AGAAGTACATGTTTCATTGTAGAGAATTTGGAACTGTAGAAGAGAATCAAGAAGAAAAAT 3035  
  
Qy 3594 AAAAATCAGCTGTTGTAATCACCTAGCAAAA 3624  
|||||  
Db 3036 AAAAATCAGCTGTTGTAATCGCCTAGCCAAA 3066